Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry

A. Selvarajah, A. H. Tavenier, W. L. Bor, Alfons J. H. M. Houben, S. Rasoul, E. Kaplan, K. Teeuwen, S. H. Hofma, E. Lipsic, G. Amoroso, M. A. H. van Leeuwen, J. M. ten Berg, A. W. J. van 't Hof, R. S. Hermanides*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number292
Number of pages7
JournalBMC Cardiovascular disorders
Volume21
Issue number1
DOIs
Publication statusPublished - 12 Jun 2021

Keywords

  • Cangrelor
  • P2Y(12) inhibitors
  • Percutaneous coronary intervention
  • Platelet inhibition
  • ELEVATION MYOCARDIAL-INFARCTION
  • PLATELET INHIBITION
  • DISTAL EMBOLIZATION
  • IMPAIRED BIOAVAILABILITY
  • STENT THROMBOSIS
  • CLOPIDOGREL
  • TICAGRELOR
  • THERAPY
  • IMPACT
  • TRANSITION

Cite this